⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
ApprovedPsychedelic

2C-B

Formula Pending

Molecular Mass
N/A
CAS Registry
N/A
Risk Class
LOW
Last Audit
Jan 1, 2024

Research Abstract

Psychedelic (4-Bromo-2,5-dimethoxyphenethylamine)

We often categorize 2C-B as merely a psychedelic, lumped in with the likes of LSD or psilocybin. However, chemically speaking, 2C-B is a phenethylamine, which gives it a unique profile distinct from tryptamines, both in terms of its molecular structure and its subjective effects. While tryptamines like LSD primarily act on the 5-HT2A receptor, 2C-B's action extends beyond this, making it not just a simple 'hallucinogen' but a compound with a multifaceted interaction with our brain's chemistry.

2C-B acts as a partial agonist at several serotonin receptors, particularly the 5-HT2A and 5-HT2C receptors, which are central to its psychoactive effects. Unlike pure agonists that fully activate a receptor, partial agonists provide a subtler activation, akin to a dimmer switch rather than a light switch. This nuanced interaction is why 2C-B can produce a spectrum of effects from mild euphoria to profound visual hallucinations. Its chemical structure, with two methoxy groups at positions 2 and 5 and a bromine atom at position 4, is crucial for its receptor affinity and psychoactive properties. Additionally, it moderately influences dopamine and norepinephrine pathways, contributing to its unique blend of stimulant and psychedelic effects.

In practical terms, the pharmacokinetics of 2C-B reveal a bioavailability of approximately 50% when taken orally, with a half-life ranging between 4 to 8 hours. It is metabolized primarily in the liver, involving demethylation and deamination pathways. Currently, 2C-B holds no approved medical use and is classified as a Schedule I substance under the United Nations Convention on Psychotropic Substances. However, it is being researched for its potential therapeutic effects, particularly in controlled settings for anxiety and PTSD. Despite its generally favorable safety profile with low incidence of severe adverse effects, risks include potential serotonin syndrome when combined with other serotonergic agents. As research continues, understanding its regulatory landscape and ensuring safe laboratory practices will be essential for exploring its full potential.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

TherapeuticClinical Research

Nomenclature

2C-B

Reference Material

  1. [1] Nichols DE. • Psychedelics. • Pharmacological Reviews. 2016;68(2):264-355.
  2. [2] Shulgin A, Shulgin A. • PiHKAL: A Chemical Love Story. • Transform Press. 1991.
  3. [3] United Nations • Convention on Psychotropic Substances • 1971.